

DETAILED ACTION

1. Applicant's response and amendments received April 10, 2008 are acknowledged.

Claims 1-28, 31, 34-77, 80-88, 91-95, 97-103, 105-116, 118-122 have been canceled.

Claims 29, 33, and 78 have been amended.

Claims 126-154 have been added.

Claims 29, 30, 32, 33, 78, 79, 89, 90, 96, 104, 117, and 123-154 are pending in the instant application.

2. Applicant's response and amendments received April 10, 2008 have overcome all outstanding grounds of rejection. Specifically, the claims as amended recite methods of using antibodies isolated from hybridomas identified by name and ATCC deposit number. These specific named hybridomas are not disclosed in the prior art. Applicant has deposited these hybridomas and has satisfied the deposit requirements for biological materials as is documented in the Declaration Concerning the Deposit of a Biological Material signed by Alan L. Koller, Ph.D., Associate General Counsel for Purdue Pharma L.P. received as part of the April 10, 2008 response.

Examiner's Amendment

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with William Coblenz on April 22, 2008.

In claim 33, the word "and" has been deleted from line 11.

Art Unit: 1644

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is (571)272-2934. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on 571-272-0878. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Szperka, Ph.D.
Primary Examiner
Art Unit 1644

/Michael Szperka, Ph.D./
Primary Examiner, Art Unit 1644